Article: article from journal or magazin.
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Pharmacogenomics of HIV Therapy: Summary of a Workshop Sponsored by the National Institute of Allergy and Infectious Diseases
HIV Clinical Trials
Approximately 1 million people in the United States and over 30 million worldwide are living with human immunodeficiency virus type 1 (HIV-1). While mortality from untreated infection approaches 100%, survival improves markedly with use of contemporary antiretroviral therapies (ART). In the United States, 25 drugs are approved for treating HIV-1, and increasing numbers are available in resource-limited countries. Safe and effective ART is a cornerstone in the global struggle against the acquired immunodeficiency syndrome. Variable responses to ART are due at least in part to human genetic variants that affect drug metabolism, drug disposition, and off-site drug targets. Defining effects of human genetic variants on HIV treatment toxicity, efficacy, and pharmacokinetics has far-reaching implications. In 2010, the National Institute of Allergy and Infectious Diseases sponsored a workshop entitled, Pharmacogenomics A Path Towards Personalized HIV Care. This article summarizes workshop objectives, presentations, discussions, and recommendations derived from this meeting.
HIV therapy, pharmacogenetics, pharmacogenomics, workshop, SINGLE-NUCLEOTIDE POLYMORPHISMS, ANTIRETROVIRAL THERAPY, PLASMA-CONCENTRATIONS, HIV-1-INFECTED INDIVIDUALS, SLCO1B1 POLYMORPHISMS, EFAVIRENZ, HYPERSENSITIVITY, NEVIRAPINE, CYP2B6, ABACAVIR
Web of science
Last modification date